{"id":4745,"date":"2017-01-07T20:19:46","date_gmt":"2017-01-08T01:19:46","guid":{"rendered":"http:\/\/www.newlonkong.com\/English\/?p=4745"},"modified":"2017-01-07T20:20:14","modified_gmt":"2017-01-08T01:20:14","slug":"biomarin-pharmaceutical-inc-bmrn","status":"publish","type":"post","link":"https:\/\/www.newlonkong.com\/English\/biomarin-pharmaceutical-inc-bmrn\/","title":{"rendered":"BioMarin Pharmaceutical Inc. (BMRN)"},"content":{"rendered":"<p><a href=\"http:\/\/www.newlonkong.com\/English\/markets\/new-york\/list-of-stocks-us\/biomarin-pharmaceutical-inc-bmrn\/\">BioMarin Pharmaceutical Inc. (BioMarin) <\/a>develops and commercializes pharmaceuticals for various diseases and medical conditions. The Company&#8217;s product portfolio consists of approximately five approved products, and multiple clinical and pre-clinical product candidates. Its approved products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>BioMarin Pharmaceutical Inc. (BioMarin) develops and commercializes pharmaceuticals for various diseases and medical conditions. The Company&#8217;s product portfolio consists of approximately five approved products, and multiple clinical and pre-clinical product candidates. Its approved products include Vimizim (elosulfase alpha), Naglazyme (galsulfase),<span class=\"ellipsis\">&hellip;<\/span><\/p>\n<div class=\"read-more\"><a href=\"https:\/\/www.newlonkong.com\/English\/biomarin-pharmaceutical-inc-bmrn\/\">Read more &#8250;<\/a><\/div>\n<p><!-- end of .read-more --><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"ngg_post_thumbnail":0,"footnotes":""},"categories":[1],"tags":[872,873],"class_list":["post-4745","post","type-post","status-publish","format-standard","hentry","category-uncategorized","tag-biomarin","tag-bmrn"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.newlonkong.com\/English\/wp-json\/wp\/v2\/posts\/4745","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newlonkong.com\/English\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newlonkong.com\/English\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newlonkong.com\/English\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newlonkong.com\/English\/wp-json\/wp\/v2\/comments?post=4745"}],"version-history":[{"count":1,"href":"https:\/\/www.newlonkong.com\/English\/wp-json\/wp\/v2\/posts\/4745\/revisions"}],"predecessor-version":[{"id":4746,"href":"https:\/\/www.newlonkong.com\/English\/wp-json\/wp\/v2\/posts\/4745\/revisions\/4746"}],"wp:attachment":[{"href":"https:\/\/www.newlonkong.com\/English\/wp-json\/wp\/v2\/media?parent=4745"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newlonkong.com\/English\/wp-json\/wp\/v2\/categories?post=4745"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newlonkong.com\/English\/wp-json\/wp\/v2\/tags?post=4745"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}